While recruitment halts keep rolling through studies run by $GSK, $LLY, $JNJ, $NVS, today $PFE said it would begin resuming trial enrollment (where permitted by conditions/authorities).

@ByJonGardner has more here: 

https://t.co/jCjDkus1kX